Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 11/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.57 |
| ▸ | STS | P08842 | 3/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888897 | 1.00 | HSD17B1 (0.74) | HSD17B1CYP19A1STSESR1ESR2 | |
| SCHEMBL12888948 | 0.89 | HSD17B1 (0.72) | HSD17B1CYP19A1STSESR1ESR2 | |
| SCHEMBL12888950 | 0.89 | HSD17B1 (0.72) | HSD17B1CYP19A1STSESR1ESR2 | |
| SCHEMBL1234800 | 0.89 | HSD17B1 (0.72) | HSD17B1CYP19A1STSESR1ESR2 | |
| SCHEMBL12888935 | 0.89 | HSD17B1 (0.70) | HSD17B1CYP19A1STSESR1ESR2 | |
| SCHEMBL12904595 | 0.89 | HSD17B1 (0.70) | HSD17B1CYP19A1STSESR1ESR2 | |
| SCHEMBL1236913 | 0.88 | HSD17B1 (0.69) | HSD17B1CYP19A1STSESR1ESR2 | |
| SCHEMBL1236911 | 0.88 | HSD17B1 (0.69) | HSD17B1CYP19A1STSESR1ESR2 | |
| SCHEMBL12888928 | 0.87 | HSD17B1 (0.68) | HSD17B1CYP19A1STSESR1ESR2 | |
| SCHEMBL1237349 | 0.87 | HSD17B1 (0.68) | HSD17B1CYP19A1STSESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192258-A1 | Antiangiogenic agents | AGOSTON GREGORY E (US) | 2005-09-01 | — | — | US | claimed |
| US-8273383-B2 | Administration of 2-methoxyestradiol or it derivatives such as colchicine or combretastatin A-4; for treating and/or preventing a pregnancy related disease; safer and more effective | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-09-25 | — | — | US | disclosed |
| US-20080160105-A1 | Methods and Compositions For Treatment of Preeclampsia | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-07-03 | — | — | US | disclosed |
| US-7135581-B2 | Antiangiogenic agents | ENTREMED, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20050192258-A1 | Antiangiogenic agents | AGOSTON GREGORY E (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192258-A1 | Antiangiogenic agents | VEGFA, PGF, TEK | HSD17B1 220/4885CYP19A1 21/4885STS 1397/4885 |
| US-20080160105-A1 | Methods and Compositions For Treatment of Preeclampsia | PGF, SHBG, HSD17B11 | HSD17B1 24/4885CYP19A1 26/4885STS 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.